Clinical Trial Search

Primary: HPV-Specific T Cell Response Rate — 0.333 proportion of participants

Primary: Base Study: Geometric Mean Titers (GMTs) for Each of the HPV Types Contained in the Vaccine (9- to 15-Year-Old Females [Lot 1] and 16- to 26-Year-Old Females [Lot 1])…

Primary: Retention — 63; 69 Participants — p=.601

Primary: Disease Specific Survival (DSS) — 29; 15; 15 participants

Primary: Female Sexual Function Index (FSFI) Score — 0.8; 1.2; 0.9; 0.7 score on a scale

Primary: Pain Following HPV Vaccine — 17; 32 participants

Primary: Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies — 36791.8; 10053.1; 16486.9; 2257.9 titer

Primary: Number of Subjects Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies — 92; 94 Participants

Primary: Change in Attitudes About HPV Vaccine — .16; -.08 units on a scale — p=.003

Primary: Percentage of Patients Free of Grade 3+ Late Toxicity — 86 percentage of participants

Primary: To Explore if Ribavirin Therapy for 2 Weeks Decreases Tumor Expression — 4; 2; 3 Participants

Primary: Titers of Anti-Papillomavirus 16 (Anti-HPV-16) and Anti-human Papillomavirus 18 (Anti-HPV-18) Antibodies — 5844.6; 10500.9; 7741.6; 13045.3 EL.U/mL

Primary: Screening Uptake — 2519; 0; 2618; 599 participants

Primary: Number of Seroconverted Subjects for Anti-Human Papillomavirus (Anti-HPV)-16 at Month 7 — 62; 27; 31; 23 Participants

Primary: Number of Young Adults Who Received Any Dose of the HPV Vaccine During the Study Period — 8; 9; 3 participants — p=.36